Govindan R et al. -Patients with squamous NSCLC have a poor prognosis and limited treatment options. The current study investigated the efficacy and safety of first-line ipilimumab or placebo plus paclitaxel and carboplatin in patients with advanced squamous NSCLC.It was shown that the addition of ipilimumab to first-line chemotherapy did not prolong OS compared with chemotherapy alone.